Want to see PRE full AI Analyst Report?
Prenetics Group (PRE) AI Stock Analysis
Prenetics Group
(NASDAQ:PRE)
The score is held back primarily by weak financial quality (persistent losses and multi-year cash burn) and bearish technicals (downtrend across key moving averages and negative MACD). These are partially offset by a notably strong and improving operating narrative from the latest earnings call, including raised guidance, rapidly scaling revenue/customer metrics, improving unit economics, and secured financing to fund growth.
Prenetics Group (PRE) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $273.04M
- Dividend Yield
- ―
- Average Volume (3M)
- 218.39K
- Price to Earnings (P/E)
- -3.9
- Beta (1Y)
- 0.35
- Revenue Growth
- 182.05%
- EPS Growth
- -5.43%
- Country
- US
- Employees
- 98
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Household & Personal Products
Prenetics Group Business Overview & Revenue Model
Company Description
Prenetics Global Limited is a consumer health sciences company that has pivoted to focus on a consumer health and longevity platform. The company's main brand is IM8, which offers science-backed nutritional supplements. It also operates CircleDNA, a...
How the Company Makes Money
Prenetics makes money primarily by selling diagnostic and genetic testing products and services. Its revenue model generally includes: (1) Test kit and service sales: monetization through one-time purchases of consumer-facing at-home tests (where off...
Prenetics Group Earnings Call Summary
The call presented a strong growth story with multiple concrete operational and commercial milestones: record revenues, dramatic customer growth, improving unit economics, raised guidance, a $1B financing commitment, and ongoing clinical trials that enhance credibility. The primary negatives are high near-term marketing-driven losses, dependence on financing to fund customer acquisition, and the relative youth of cohorts and trials (outcomes pending). On balance, the material upward momentum, improving metrics (CAC, margins, contribution profit), and secured funding outweigh the current losses and risks.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management raised full‑year 2026 revenue guidance to $220–230M (IM8 $215–222M) and initiated 2027 guidance of $400M+, while guiding Q3 IM8 revenue of $61.5–62.5M (Prenetics $63–64M) with an implied Q4 of ~$81.2M; Q2 revenue was $46.5M (IM8 $45M), +29% sequential and 3.9x year‑over‑year, with 65% gross margin and ~46% contribution margin. The company added ~118k new customers in Q2 (July cohort ~47k), reached ~140k active subscribers, and hit a July monthly revenue near $21M (monthly run‑rate ≈ $251M after July); CAC improved to ~$239 in July (vs ~$301 in Q2, ~$305 in Q1) and each $1 of acquisition spend has returned ~$1.52 of gross profit to date. General Catalyst committed $1B (funding ~70% of acquisition spend), July showed adjusted free‑cash‑flow positivity, the balance sheet held ~$109M of cash/current financial assets, and management expects H2 adjusted EBITDA loss to narrow to roughly negative $8M–$12M (vs H1 ≈ negative $24.6M).
Prenetics Group Financial Statement Overview
Summary
Revenue and gross margin trends are improving materially, and leverage is currently low with a solid equity base. However, profitability remains deeply negative and recent operating/free cash flow has been consistently negative, indicating ongoing cash burn and an unproven path to sustained earnings.
Income Statement
34NegativeBalance Sheet
62PositiveCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 142.56M | 92.39M | 30.62M | 21.74M | 13.16M | 12.53M |
| Gross Profit | 89.25M | 48.79M | 15.40M | 8.83M | 3.62M | 3.60M |
| EBITDA | -62.52M | -32.19M | -51.57M | -47.90M | -218.04M | -209.16M |
| Net Income | -67.61M | -37.71M | -46.30M | -62.72M | -190.45M | -174.01M |
Balance Sheet | ||||||
| Total Assets | 153.66M | 203.52M | 213.57M | 254.17M | 312.13M | 148.51M |
| Cash, Cash Equivalents and Short-Term Investments | 109.39M | 61.49M | 62.81M | 72.74M | 184.12M | 45.19M |
| Total Debt | 682.00K | 2.20M | 5.77M | 2.37M | 6.65M | 491.67M |
| Total Liabilities | 60.73M | 29.01M | 42.23M | 44.01M | 68.67M | 549.40M |
| Stockholders Equity | 93.01M | 174.60M | 170.39M | 206.36M | 237.06M | -400.81M |
Cash Flow | ||||||
| Free Cash Flow | -34.14M | -22.02M | -29.94M | -14.68M | 8.17M | 2.00M |
| Operating Cash Flow | -49.39M | -21.81M | -28.87M | -13.76M | 14.51M | 13.42M |
| Investing Cash Flow | 54.97M | -35.79M | 38.54M | -82.95M | -46.14M | -22.02M |
| Financing Cash Flow | 1.42M | 37.54M | -3.34M | -4.70M | 143.32M | 29.32M |
Prenetics Group Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRE, the sentiment is Negative. The current price of 16.12 is below the 20-day moving average (MA) of 18.44, below the 50-day MA of 21.54, and below the 200-day MA of 19.60, indicating a bearish trend. The MACD of -1.37 indicates Positive momentum. The RSI at 32.77 is Neutral, neither overbought nor oversold. The STOCH value of 17.19 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRE.
Prenetics Group Risk Analysis
Prenetics Group disclosed 58 risk factors in its most recent earnings report. Prenetics Group reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksPrenetics Group Peers Comparison
Overall Rating
XGN57Neutral- PRE55Neutral
BNR52Neutral
STIM49Neutral
ACRS41Neutral
MDXH41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| XGN | 57Neutral | $206.16M | -9.27 | -121.62% | ― | 20.83% | 9.70% |
| PRE | 55Neutral | $271.68M | -3.88 | -49.17% | ― | 182.05% | -5.43% |
| BNR | 52Neutral | $134.95M | -1.37 | -12.97% | ― | -3.65% | 51.30% |
| STIM | 49Neutral | $206.11M | -7.59 | -127.86% | ― | 23.01% | 60.22% |
| ACRS | 41Neutral | $570.34M | -6.22 | -59.20% | ― | -59.34% | 57.30% |
| MDXH | 41Neutral | $14.92M | -0.26 | 142.63% | ― | 12.75% | 16.23% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PRE | Prenetics Group Limited | 16.12 | 3.78 | 30.63% | |
| ACRS | Aclaris Therapeutics Inc. | 3.61 | 1.29 | 55.60% | |
| MDXH | Mdxhealth S.A. | 0.15 | -4.34 | -96.64% | |
| STIM | Neuronetics | 2.43 | 0.15 | 6.58% | |
| XGN | Exagen | 7.60 | -1.96 | -20.50% | |
| BNR | Burning Rock Biotech Ltd. | 13.25 | 1.46 | 12.38% |
Prenetics Group Corporate Events
Prenetics’ IM8 Strikes Multiyear Deal as NBA’s Official Nutrition Partner in Australia and Southeast Asia
Prenetics Global Limited’s wellness subsidiary IM8 has entered into a multiyear collaboration with the National Basketball Association, announced on Oct. 12, 2026 in Hong Kong, that makes IM8 the Official Nutrition Partner of the NBA in Austral...
Prenetics Leaders Boost $3.75 Million Insider Stakes After Strong Q2 and IM8 Surge
Prenetics Global Limited reported that its CEO Danny Yeung and CFO Brian Rosin bought a combined $1.0 million of company shares in the open market between August 20 and August 25, 2026, following the release of its second-quarter 2026 results. These...
Prenetics’ IM8 Brings Lily Collins On Board as Global Ambassador and Shareholder Amid Raised 2026–2027 Guidance
Prenetics Global Limited, the parent of premium health and longevity brand IM8, operates in the consumer health sector with a focus on science-backed daily nutrition systems. Co-founded with David Beckham, IM8’s flagship Daily Ultimate Essentia...
Prenetics’ IM8 Drives 288% Q2 Revenue Surge and Turns Cash Flow Positive
On August 18, 2026, Prenetics reported unaudited second-quarter 2026 results showing total revenue of $46.5 million, up about 288% year-on-year and in line with guidance. IM8 accounted for $45.0 million, rising roughly 359% year-on-year and marking a...
Prenetics Names Veteran Wall Street Analyst Caroline Levy to Board as Independent Director
On August 17, 2026, Prenetics Global Limited announced the appointment of veteran Wall Street consumer analyst Caroline Levy as an independent director to its Board. Levy, known for more than 30 years of equity research experience and leadership role...
Prenetics Secures $1 Billion General Catalyst Growth Financing for IM8 Business
On July 14, 2026, Prenetics Global Limited announced it had closed a $1 billion growth financing arrangement with General Catalyst’s Customer Value Fund to support the sales and marketing expansion of its IM8 business. The deal, documented in a...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 22, 2026